First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Xinan Sheng, Zengjun Wang et al.|The Lancet Oncology|2025Cited by 10
Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma PathogenesisWeimin Zhou, Xinhua Tu|Journal of Cancer|2024Cited by 4